OX40 Ligand

OX40 Ligand

OX40 Ligand Overview

Molecule Name
Tumor necrosis factor ligand superfamily member 4
Synonyms
OX40L,TNFSF4,CD252,Glycoprotein Gp34,TXGP1,CD134 ligand,CD134L
Drug Development Progress
Drugs in Clinical Trials13
Approved Drugs0
Highest Development StagePhase 3 Clinical
Target Synonym
CD134L,OX-40L,TNLG2B,OX4OL,GP34,CD252 Antigen,CD134 Ligand,TAX transcriptionally-activated glycoprotein 1,Tax-Transcriptionally Activated Glycoprotein 1, 34kD,CD252,OX40 ligand,OX40L,TNFSF4,Tumor necrosis factor ligand superfamily member 4,Glycoprotein Gp34,TNF Superfamily Member 4,TXGP1,Tax-Transcriptionally Activated Glycoprotein 1 (34kD),Tumor Necrosis Factor (Ligand) Superfamily, Member 4,Tumor Necrosis Factor (Ligand) Superfamily Member 4,Tumor Necrosis Factor Superfamily Member 4,Tumor Necrosis Factor Ligand 2B,OX40 Antigen Ligand
Background
Tumor necrosis factor ligand superfamily member 4 (TNFSF4) is also known as glycoprotein Gp34, OX40 ligand (OX40L), TAX transcriptionally-activated glycoprotein 1 and CD252, which belongs to the tumor necrosis factor family. TNFSF4 is the ligand for CD134 and is expressed on such cells as DC2s (a subtype of dendritic cells) enabling amplification of Th2 cell differentiation. The interaction of TNFSF4-TNFSF4 is involved in the pathogenesis of multiple autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), carotid artery disease and cancer. Furthermore, similar to other TNF superfamily members, membrane-bound OX40 Ligand (TNFSF4) exists as a homotrimer. Human TNFSF4 shares 46% amino acid sequence identity with its mouse counterpart.

OX40 Ligand Product List

Species
  • Human(9)
  • Mouse(4)
  • Cynomolgus / Rhesus macaque(3)
  • Canine(1)
  • Rabbit(1)
  • Rat(1)
Tag
  • His Tag(10)
  • His Tag & Avi Tag(3)
  • Fc Tag(2)
  • Fc Tag & Avi Tag(2)
  • Mouse IgG Fc Tag(2)
Host
  • HEK293(19)
Conjugate
  • Unconjugated(14)
  • Biotin-labeled(5)
Grade
  • RUO(17)
  • PG (pre-GMP)(2)
Low Endotoxin
  • Yes(8)
  • No(11)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&PriceAdd to Cart
OX40 Ligand
Human OX40 Ligand / TNFSF4 Protein, His Tag, active trimer
Human
HEK293
HPLCSDS-PAGE
SPR

$1340.00

250ug
OX40 Ligand
Human OX40 Ligand / TNFSF4 Protein, His Tag, active trimer
Human
HEK293
HPLCSDS-PAGE
SPR

$1340.00

250ug
OX40 Ligand
Human OX40 Ligand / TNFSF4 Protein, Fc Tag, premium grade
Human
HEK293
MALSSDS-PAGE
ELISA

$300.00

100ug
OX40 Ligand
Human OX40 Ligand / TNFSF4 Protein, His Tag, active trimer, low endotoxin (Mass Spec & MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISABLI

$430.00

50ug
OX40 Ligand
Human OX40 Ligand / TNFSF4 Protein, His Tag, active trimer, low endotoxin (Mass Spec & MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISABLI

$430.00

50ug
OX40 Ligand
HOTAvitag
OXL-H82Q5
Biotinylated Human OX40 Ligand / TNFSF4 Protein, His,Avitag™, active trimer (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$435.00

25ug
OX40 Ligand
Cynomolgus / Rhesus macaque OX40 Ligand Protein, His Tag, active trimer, low endotoxin (MALS verified)
Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISA

$380.00

100ug
OX40 Ligand
Canine OX40 Ligand / TNFSF4 Protein, His Tag (MALS verified)
Canine
HEK293
MALSSDS-PAGE
ELISA

$360.00

100ug
OX40 Ligand
Avitag
OXL-C52Q3
Biotinylated Cynomolgus / Rhesus macaque OX40 Ligand / TNFSF4 Protein, His,Avitag™ (MALS verified)
Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
OX40 Ligand
Human OX40 Ligand / TNFSF4 Protein, Mouse IgG2a Fc Tag, low endotoxin
Human
HEK293
SDS-PAGE
ELISABLIFlow

$380.00

100ug
You Have Viewed 1-10 Of 19 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

FAQ

Before an OX40/OX40L-targeted candidate advances into nonclinical studies, what species-specific OX40L reagents and receptor-binding data are available for cross-species assessment?

The ACROBiosystems portfolio covers human, cynomolgus/rhesus macaque, mouse, rat, rabbit and canine OX40L proteins. Active-trimer and SEC-MALS characterization is available for selected formats rather than uniformly across every species, while receptor-binding validation is provided for specific human, nonhuman-primate and other species combinations.

Soluble OX40L binding does not show whether an antibody recognizes the full-length target on the cell surface or modulates OX40 signaling. What complementary tools address these later characterization needs?

A human OX40L stable cell line provides full-length cell-surface target presentation for antibody-binding characterization. ACROBiosystems also offers an OX40 luciferase reporter cell for pathway-dependent functional readouts, including inhibition mediated by OX40L-neutralizing antibodies.

Early screening of OX40–OX40L blockers requires a scalable readout of interaction inhibition. Which assay format supports this stage of candidate assessment?

ACROBiosystems offers a related human OX40/OX40L inhibitor screening kit based on TR-FRET. The homogeneous, no-wash format provides a direct receptor–ligand inhibition readout and has been validated with antibodies against the OX40–OX40L axis. It measures disruption of molecular binding rather than downstream cellular signaling.

Why is the trimeric structure of OX40L important in binding studies?

OX40L naturally forms a homotrimer, which is relevant to its receptor-binding behavior. Human OX40 Ligand Protein, His Tag (OXL-H52Q8) has SEC-MALS characterization supporting its trimeric molecular state. Reviewing oligomeric-state data can help researchers assess whether a protein format suits their intended interaction study.

The oligomeric state of OX40L can affect receptor engagement. How are the higher-order structure and receptor-binding activity of recombinant OX40L characterized?

Selected ACROBiosystems OX40L proteins are supplied as active-trimer formats with SEC-MALS data supporting their solution molecular-weight distribution. Receptor recognition is evaluated separately through ELISA, BLI or cell-based binding data. Together, these measurements address both molecular state and binding activity without treating SEC-MALS alone as evidence of functional signaling.
Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
AmlitelimabKY-1005; SAR-445229Phase 3 ClinicalKymab Ltd, Sanofi
Alopecia Areata; Asthma; Celiac Disease; Dermatitis, Atopic; Eczema; Hidradenitis; Immune System Diseases; Lung Diseases, Interstitial; Scleroderma, Systemic
Details
APG-279APG279; APG-990/APG777Phase 2 ClinicalApogee Therapeutics Inc
Dermatitis, Atopic
Details
IMB-101 (IMBiologics)IMB-101 (IMBiologics); HDM-3019; IMB101 (IMBiologics); HDM3019; NAV-240Phase 2 ClinicalIMBiologics Corp
Arthritis, Rheumatoid; Hidradenitis Suppurativa
Details
IBI356IBI-356; IBI356Phase 2 Clinical
Autoimmune Diseases; Dermatitis, Atopic
Details
RP-3RP-3Phase 2 ClinicalReplimune Inc
Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
HS-130HS-130Phase 1 ClinicalHeat Biologics
Solid tumours
Details
mRNA-2752mRNA-2752Phase 1 ClinicalAstrazeneca Plc, Moderna Inc
Lymphoma; Neoplasms; Solid tumours
Details
MQ-710MQ-710Phase 1 ClinicalImvaq Therapeutics Corp, Memorial Sloan Kettering Cancer Center
Adenocarcinoma, Sebaceous; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Hemangiosarcoma; Melanoma; Neoplasm Metastasis; Neoplasms; Paget Disease, Extramammary; Sarcoma, Kaposi; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
OX-118OX-118Phase 1 ClinicalOxion Biologics AB
Autoimmune Diseases; Immune System Diseases; Rheumatic Diseases
Details
M-5542M5542; M-5542Phase 1 ClinicalMerck & Co Inc
Details
ABCL-575ABCL-575; ABCL575Phase 1 ClinicalAbCellera Biologics Inc
Dermatitis, Atopic
Details
APG-990APG-990; APG990; PR-007; PR007Phase 1 ClinicalParagon Therapeutics Inc
Dermatitis, Atopic
Details
SAR-443726SAR-443726Phase 1 ClinicalSanofi
Dermatitis, Atopic
Details
Customer Reviews